Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Litemuppon May 17, 2018 6:10pm
125 Views
Post# 28049205

RE:Listen up....I called the last NR

RE:Listen up....I called the last NRU sound like an investment firm outfit. Either way I agree with the whole pharmaceutical advantage. Some of these big companies have pain meds in portfolios worth billions. I happen to be on 2 pain medicines from Pfizer and they are both blockbuster drugs celebrex and lyrica.
busy4life wrote: This is getting ready for a big run. I am tight with a few insiders. A lot of stuff happening behind the scenes and KALY has already gotten attention from some tier 2 pharma compairs, names of which I cannot disclose. If all goes well this will get halted and straight bought out. Pharma is itching to get into cannabis treatments and instead of reinventing the wheels they will start acquiring boutique research companies like KALY that are targeting medical cannabis therapies. Their biggest advantage is the Israel connection. Good luck.


Bullboard Posts